Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsCash from RestructuringChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Depreciation and Depletion (2020 - 2023)

LENZ Therapeutics (LENZ) reported Depreciation and Depletion of $100000.0 for Q4 2023, down 85.71% year-over-year from $700000.0 in Q4 2022, and down 87.5% on a QoQ basis from $800000.0 in Q3 2023.

LENZ Therapeutics (LENZ) has 4 years of Depreciation and Depletion data on file, last reported at $100000.0 in Q4 2023.

  • Quarterly Depreciation and Depletion fell 85.71% year-over-year to $100000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $2.4 million (changed 0.0% YoY) and the FY2023 annual result came in at $2.4 million, changed 0.0% from the prior year.
  • Depreciation and Depletion fell to $100000.0 in Q4 2023 per LENZ's latest filing, from $800000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $800000.0 in Q2 2023 and bottomed at $1000.0 in Q2 2020.
  • The 4-year median for Depreciation and Depletion is $350000.0 (2021), against an average of $400071.4.
  • The widest annual swing landed in 2021, when Depreciation and Depletion soared 9900.0%; it then slumped 85.71% in 2023.
  • Tracing LENZ's Depreciation and Depletion over 4 years: stood at $100000.0 in 2020, then surged by 200.0% to $300000.0 in 2021, then soared by 133.33% to $700000.0 in 2022, then slumped by 85.71% to $100000.0 in 2023.
  • Per Business Quant, the three latest LENZ Depreciation and Depletion figures stand at $100000.0 (Q4 2023), $800000.0 (Q3 2023), and $800000.0 (Q2 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation and Depletion (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1,395.22
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 LENZ Therapeutics 235.77 Mn 235.77 Mn 825,000.00 -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 100,000.00
Dec 31, 2023 100,000.00
Sep 30, 2023 800,000.00
Sep 30, 2023 800,000.00
Jun 30, 2023 800,000.00
Jun 30, 2023 800,000.00
Mar 31, 2023 700,000.00
Mar 31, 2023 700,000.00
Dec 31, 2022 700,000.00
Dec 31, 2022 700,000.00
Sep 30, 2022 700,000.00
Sep 30, 2022 700,000.00
Jun 30, 2022 600,000.00
Jun 30, 2022 600,000.00
Mar 31, 2022 400,000.00
Mar 31, 2022 400,000.00
Dec 31, 2021 300,000.00
Dec 31, 2021 300,000.00
Sep 30, 2021 200,000.00
Sep 30, 2021 200,000.00
Jun 30, 2021 100,000.00
Jun 30, 2021 100,000.00
Mar 31, 2021 100,000.00
Mar 31, 2021 100,000.00
Dec 31, 2020 100,000.00
Dec 31, 2020 100,000.00
Jun 30, 2020 1,000.00
Jun 30, 2020 1,000.00